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Abstract
Background: Pim-1, 2 and 3 are a group of enzymes related to the calcium calmodulin family of
protein kinases. Over-expression of Pim-1 and Pim-2 in mice promotes the development of
lymphomas, and up-regulation of Pim expression has been observed in several human cancers.
Results: Here we show that the pim kinases are constitutively active when expressed in HEK-293
cells and are able to phosphorylate the Bcl-2 family member Bad on three residues, Ser112, Ser136
and Ser155 in vitro and in cells. In vitro mapping showed that Pim-2 predominantly phosphorylated
Ser112, while Pim-1 phosphorylated Ser112, but also Ser136 and Ser155 at a reduced rate
compared to Ser112. Pim-3 was found to be the least specific for Ser112, and the most effective at
phosphorylating Ser136 and Ser155. Pim-3 was also able to phosphorylate other sites in Bad in vitro,
including Ser170, another potential in vivo site. Mutation of Ser136 to alanine prevented the
phosphorylation of Ser112 and Ser155 by Pim kinases in HEK-293 cells, suggesting that this site
must be phosphorylated first in order to make the other sites accessible. Pim phosphorylation of
Bad was also found to promote the 14-3-3 binding of Bad and block its association with Bcl-XL.
Conclusion: All three Pim kinase family members predominantly phosphorylate Bad on Ser112
and in addition are capable of phosphorylating Bad on multiple sites associated with the inhibition
of the pro-apoptotic function of Bad in HEK-293 cells. This would be consistent with the proposed
function of Pim kinases in promoting cell proliferation and preventing cell death.
Background
Pim-1, 2 and 3 make up a group of closely related mam-
malian serine/threonine kinases that form part of the cal-
modulin dependent protein kinase family [1,2]. Pim-1
was first identified as an oncogenic gene in murine T-cell
lymphomas, which became activated after pro-viral inser-
tion in the 3'UTR of the Pim-1 gene [3]. Insertion in this
region stabilised the mRNA for Pim-1 thus up-regulating
the protein [4]. Over-expression of the Pim-1 gene in B
and T cells in transgenic mice resulted in a high level of
lymphoma development in these mice, confirming the
oncogenic properties of this protein [5,6]. A second
related gene, Pim-2, was also identified as a common site
of viral insertion in murine lymphomas [7]. Like Pim-1
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the over-expression of Pim-2 in transgenic mice predis-
poses the mice to the development of lymphoma [8]. The
precise mechanism by which Pim-1 and 2 promote the
formation of lymphomas is not fully understood, how-
ever it has been suggested that Pim-1 synergises with c-
myc in this process [8-10]. Pim-1 also appears to be
important in the development of human cancers, as the
Pim-1 gene maps to an area showing karyotypic abnor-
malities in leukaemia, and the mRNA for Pim-1 has been
shown to be up-regulated in prostate cancer and leukae-
mia [11-13]. A third isoform, Pim-3, which is 72% identi-
cal to Pim-1 also exists in mammalian cells although the
oncogenic properties of this protein are less well studied.
Pim-3 has recently been shown to be up-regulated in
Ewing's tumour cell lines, is a transcriptional target for the
oncogenic EWS transcription factors and is able to pro-
mote anchorage-independent cell growth in tissue culture
models [14]. Recently, over-expression of Pim-3 has been
demonstrated in a mouse model of hepatocellular carci-
noma, although the functional role of Pim-3 was not
determined [15].
Several substrates have been suggested for Pim-1 includ-
ing mdm2 [16], p21 [17], cdc25 phosphatase [18] and c-
myb [19], all proteins involved in control of the cell cycle.
Pim-2 has been reported to maintain phosphorylation of
the translational repressor 4EBP-1 and to phosphorylate
and inactivate the pro-apoptotic protein Bad on Ser112
[20,21]. Pim-1 has also been reported to be able to phos-
phorylate Bad on Ser112 [22], however the ability of Pim-
3 to phosphorylate Bad is unknown. Both Pim-1 and Pim-
2 therefore appear to act as survival or proliferation sig-
nals in vivo. Consistent with this Pim-1 expression has
been shown to promote cytokine independent growth of
haematopoetic cells [23,24]. In contrast, less is known
about the substrates of Pim-3, and its function in vivo is
still largely unclear.
Bad is a pro-apoptotic member of the BH3 family of pro-
teins. Active Bad induces apoptosis by binding to anti-
apoptotic Bcl-2 family members such as Bcl-XL. This
allows other pro-apoptotic proteins such as BAX and BAK
to aggregate, inducing cytochrome C release from the
mitochondria and caspase activation (reviewed in [25]).
The activity of Bad is repressed by phosphorylation, and
three residues (Ser112, Ser136 and Ser155) have been
identified as the predominant in vivo phosphorylation
sites. In addition to Pim-2 several kinases have been iden-
tified as potential kinases for Bad, including PKB [26-28],
RSK [29,30], PAK [31], p70S6K [32] and PKA [33-35]. It
seems likely that multiple kinases may phosphorylate Bad
on these sites in vivo, depending on the cell type and situ-
ation. Consistent with this, several of the proposed
kinases preferentially phosphorylate one or two of the
three sites in Bad. For instance, in vitro RSK phosphor-
ylates Ser112 and to a lesser extent Ser155, while PKB
phosphorylates Ser136 and PKA preferentially phosphor-
ylates Ser155 [33]. In addition to these phosphorylation
sites, an unidentified kinase has been shown to inhibit
apoptosis by phosphorylating Bad on Ser170 [36]. Con-
versely, phosphorylation by Cdc2 of Ser128 in Bad was
found to promote the apoptotic activity of Bad [37].
In this paper we examine the specificity of Pim-1, 2 and 3
for the Ser112, 136 and 155 phosphorylation sites in Bad,
both in vitro and in HEK-293 cells.
Results
Pim kinases phosphorylate Bad on three sites in vitro
Bad has been described previously to be phosphorylated
on three sites, Ser112, Ser136 and Ser155 in vivo. Peptides
from around these sites were used as substrates for puri-
fied Pim-1, 2 or 3 in in vitro kinase assays. All three Pim
kinases were found to phosphorylate the Ser112 peptide
efficiently (Fig 1A–C). In contrast the Ser136 and Ser155
peptides were much less effective substrates for Pim-1 and
Pim-3 (Fig 1A and 1C) and very poor substrates for Pim-2
(Fig 1B). As phosphorylation of synthetic peptides does
not always give a true reflection of a kinases ability to
phosphorylate the corresponding site in a protein, the
ability of Pim kinases to phosphorylate recombinant Bad
protein was also examined. As expected Bad was phos-
phorylated by all three Pim kinases, with maximum phos-
phorylation occurring in the first 5 to 10 min (Fig 1D–F).
This activity was due to the Pim kinase, as incubation of
the Bad protein in the absence of Pim (Fig D-F), or with
kinase dead Pim (data not shown), did not result in any
incorporation of 32P into Bad. To determine the sites
phosphorylated by Pim-1, 2 or 3, recombinant Bad was
phosphorylated with 32P labelled ATP and digested with
trypsin. Peptides were then resolved by reverse phase
HPLC and ms/ms used to identify the phospho peptides
eluted (data not shown). The position of the phosphate in
each peptide was also confirmed by solid phase sequenc-
ing reactions and measuring the cycle at which radioactiv-
ity was released. Pim-1 phosphorylated 4 major peptides
in Bad, designated P1, P2 P3 and P4 (Fig 2A). Peak P1 was
found to correspond to phospho Ser155, P2 to Ser136
while both P3 and P4 corresponded to phospho Ser112
(Table 1). The different elution times of the Ser112 pep-
tides is probably explained by different oxidation states of
the methionine residue in the peptide. Analysis of the
cpm in each peak showed that Ser112 was the site most
highly phosphorylated by Pim-1, with approximately 7
times the level of phosphorylation than occurred at either
Ser136 or Ser155. This was consistent with what was
found for the rate of phosphorylation of the synthetic
peptides for each site (Fig 1A). Pim-2 was found to phos-
phorylate two major peaks that eluted at an identical posi-
tion to the P3 and P4 peaks in the Pim-1 phosphorylatedBMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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Phosphorylation of peptides derived from Bad and recombinant Bad protein by Pim kinases Figure 1
Phosphorylation of peptides derived from Bad and recombinant Bad protein by Pim kinases. A-C) Recombinant 
Pim-1 (A), Pim-2 (B) or Pim-3 (C) were incubated in in vitro kinase assays with the indicated concentrations of synthetic pep-
tides from around the three potential phosphorylation sites in Bad as described in the methods. The peptides used were 
RSRMSSYPDRG (corresponding to Ser112), RGSRSAPPNL (corresponding to Ser136) and RELRRMSDEFEGS (corresponding 
to Ser155). After 10 min at 30°C, the reactions were terminated and the amount of phosphate incorporated into the peptide 
determined. D-F) Recombinant Pim-1 (D), Pim-2 (E) or Pim-3 (F) were used to phosphorylate 2 µg of Bad as described in the 
methods. At the times indicated reactions were stopped by the addition of SDS sample buffer and the amount of phosphate 
incorporated into Bad was determined by SDS gel electrophoresis and Cerenkov counting of the Bad band.
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Phospho site mapping of Pim phosphorylation sites in Bad Figure 2
Phospho site mapping of Pim phosphorylation sites in Bad. Bad was phosphorylated by 10 mU of Pim-1 (A), Pim-2 (B) 
or Pim-3 (C) at 30°C for 10 min. Bad was then digested with trypsin as described in the methods and the resulting peptides 
resolved using an acetonitrile gradient on reverse phase HPLC. Phospho peptides were analysed by ms/ms and solid phase 
Edman sequencing to determine the phosphorylated residue. (D) Solid phase sequencing results for the peaks obtained with 
Bad phosphorylated by Pim-3. For each peptide, release of 32P was obtained within the first 7 cycles (see section D). Further 
cycles to the end of the peptides did not result in the release of more peaks of 32P (data not shown). Similar results were 
obtained for peaks 1 to 4 using Pim-1 and Pim-2 phosphorylated Bad (data not shown).
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Bad (Fig 2B). Ms/ms analysis confirmed that these pep-
tides also corresponded to Bad phosphorylated on
Ser112. Small peaks were also seen corresponding to P1
and P2 in the Pim-2 phosphorylated Bad HPLC trace, and
these were confirmed to correspond to phospho Ser155
and Ser136. The amount of phosphate incorporated at
these sites was 15 times less than that at Ser112 (Table 1).
Pim-3 phosphorylated Bad also gave peaks corresponding
to P1, P2, P3 and P4, and again these were confirmed as
Ser112, Ser136 and Ser155 by ms/ms and solid phase
sequencing (Fig 2C and 2D). Of the three kinases Pim-3
gave the highest phosphorylation of Ser136 and Ser155
compared to Ser112 in Bad (Table 1). Five further smaller
phospho peptide peaks (P5-9) were also observed in the
HPLC when Pim-3 was used to phosphorylate Bad. These
sites were not however significantly phosphorylated by
Pim-1 or Pim-2. P5 was observed in the flow through of
the column and peptides in this fraction were not identi-
fied by mass spectrometry. Prediction from the Bad
sequence shows that tryptic digest would give 2 small pep-
tides that contain serine or threonine that could have
been phosphorylated. Phosphopeptides from P9 were
also not successfully identified by mass spectrometry. P7
was identified as the peptide AATNSHHGGAGAMETR
(residues 92 to 107 of Bad) with 1 phospho group. Ms/ms
analysis suggested that this was a mixture of phosphoryla-
tion on either Thr94 or Ser96. Solid phase sequencing
confirmed this result, and also suggested that Ser96 was
the predominant site (Fig 2D). P6 and P8 were identified
by mass spectrometry as SAGTATQMR (residues 170 to
178 in Bad) phosphorylated at Ser170. The phosphoryla-
tion of Ser170 was confirmed by solid phase sequencing
for both P6 and P8. Surprisingly, solid phase sequencing
also showed that in P8 the 4th residue in the peptide was
also phosphorylated, suggesting that Thr 173 may also be
phosphorylated by Pim-3.
Pim kinases are constitutively active in HEK-293 cells and 
phosphorylate Bad on Ser112, 136 and 155
To examine the regulation of Pim-1, 2 and 3 in cells, FLAG
tagged Pim kinases were expressed in HEK-293 cells by
transient transfection. Endogenous levels of Pim-1, 2 or 3
could not be detected in HEK-293 cells with the antibod-
ies available. After serum starvation the cells well treated
with various stimuli and the activity of the Pim kinases
determined after immunoprecipitation with an anti-FLAG
antibody. All three of the Pim kinases were found to be
active in serum starved cells, and their activity was not fur-
ther increased by stimulation of the cells with mitogenic
signals (PMA or IGF), cellular stress (anisomycin, sorbitol,
UV-C or hydrogen peroxide) or AICar, an activator of
AMPK (Fig 3A).
GST-Bad expressed by transient transfection of serum
starved HEK-293 cells, in the absence of the co-expression
of any kinase, was found to be phosphorylated on Ser136,
bur not Ser112 or Ser155, as judged by immunoblotting
Table 1: Phosphorylation site analysis of Bad. Phosphorylated peptides were eluted from the HPLC (Fig 2) were identified by ms/ms 
mass spectrometry. The amino acid numbers of the peptide in murine Bad are indicated and the phosphorylation site underlined. 
Results for the release of 32P during Edman degradation cycle sequencing and phospho amino acid analysis of these fractions are also 
indicated. The percentage of 32P obtained in each HPLC peak, relative to the total 32P eluted in all the peaks is also listed (last 
column)
Kinase Peak Residue 
Numbers
Peptide Sequence Phospho-amino 
acid analysis
Solid Phase cycle 
no.
Phosphorylation 
site
% 32P
Pim-1 1 154 – 163 MSDEFEGSFK Phospho Ser 2 Ser 155 11
21 3 6  –  1 4 6 S APPNLWAAQR Phospho Ser 1 Ser 136 15
31 1 0  –  1 3 1 H S S YPAGTEEDEGMEEELSPFR Phospho Ser 3 Ser 112 60
41 1 0  –  1 3 1 H S S YPAGTEEDEGMEEELSPFR Phospho Ser 3 Ser 112 14
Pim-2 3 110 – 131 HSSYPAGTEEDEGMEEELSPFR Phospho Ser 3 Ser 112 82
41 1 0  –  1 3 1 H S S YPAGTEEDEGMEEELSPFR Phospho Ser 3 Ser 112 18
Pim-3 1 154 – 163 MSDEFEGSFK Phospho Ser 2 Ser 155 14
21 3 6  –  1 4 6 S APPNLWAAQR Phospho Ser 1 Ser 136 28
31 1 0  –  1 3 1 H S S YPAGTEEDEGMEEELSPFR Phospho Ser 3 Ser 112 27
41 1 0  –  1 3 1 H S S YPAGTEEDEGMEEELSPFR Phospho Ser 3 Ser 112 6
5 unidentified unidentified unidentified N/A unidentified 13
61 7 0  –  1 7 8 S AGTATQMR Phospho Ser 1 Ser 170 4
7 92 – 107 AATNSHHGGAGAMETR Phospho Thr/
Ser
3, 5 Thr 94 Ser 96 2
81 7 0  –  1 7 8 S AGTATQMR Phospho Ser/
Thr
1, 4 Ser 170 Thr 173 2
9 unidentified unidentified unidentified N/A unidentified 3BMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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Phosphorylation of Bad by Pim kinases in HEK-293 cells Figure 3
Phosphorylation of Bad by Pim kinases in HEK-293 cells. A) FLAG-Pim-1, Pim-2 or Pim-3 were expressed in HEK-293 
cells by transient transfection. 24 h after transfection cells were serum starved for 18 h and then stimulated with either IGF 
(100 ng/ml 5 min), sorbitol (0.5 M for 30 min), AICar (2 mM for 1 hour), UV-C (200Jm2 followed by 1 hour incubation at 
37°C), hydrogen peroxide (1 mM for 1 hour), PMA (400 ng/ml for 15 min), anisomycin (10 µg/ml for 1 hour) or left unstimu-
lated. Cells were lysed and Pim kinase activity measured by immunoprecipitation assays as described in the methods. B) GST-
Bad was transfected into HEK-293 cells along with either empty pCMV5 vector or FLAG-Pim-1, 2, or 3 expression constructs. 
24 h after transfection cells were serum starved for 18 h and then left unstimulated or stimulated with either PMA (400 ng/ml 
for 15 min) or forskolin (20 µM for 30 min). Cells were then lysed and extracts immunoblotted for Bad phosphorylated on 
Ser112, Ser136 or Ser155, total Bad and FLAG (to monitor Pim-1, 2 or 3 expression). C) GST-Bad was transfected into HEK-
293 cells with empty pCMV5 vector or active or kinase dead FLAG-Pim-1-3 expression constructs. 24 h after transfection cells 
were serum starved for 18 h and were then lysed and extracts immunoblotted for Bad phosphorylated on Ser112, Ser136 or 
Ser155, total Bad and FLAG (to monitor Pim-1, 2 or 3 expression).BMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
Page 7 of 14
(page number not for citation purposes)
Ser136 is a critical site to allow phosphorylation of Bad by Pim in cells Figure 4
Ser136 is a critical site to allow phosphorylation of Bad by Pim in cells. A) GST-Bad, or Ser112Ala, Ser136Ala, 
Ser155Ala, Ser136Asp or Ser136Glu mutants of GST-Bad were transfected into HEK-293 cells along with either empty pCMV5 
vector or a FLAG-Pim-1 expression constructs. 24 h after transfection cells were serum starved for 18 h and were then lysed 
and extracts immunoblotted with antibodies against Bad phosphorylated on Ser112, Ser136 or Ser155, total Bad or FLAG. B) 
GST-Bad, or Ser136/155Ala, Ser112/155Ala or Ser112/136Ala mutants of GST-Bad were transfected into HEK-293 cells with 
either empty pCMV5 vector or FLAG-Pim-1 expression constructs. 24 h after transfection cells were serum starved for 18 h 
and lysed and extracts immunoblotted with antibodies against Bad phosphorylated on Ser112, Ser136 or Ser155, total Bad or 
FLAG. C) GST-Bad, or Ser112Ala, Ser136Ala, Ser155Ala, Ser136Asp or Ser136Glu mutants of GST-Bad were transfected into 
HEK-293 cells along with either empty pCMV5 vector or a FLAG-Pim-1 expression constructs. 24 h after transfection cells 
were serum starved for 18 h and were then lysed and extracts immunoblotted for total Bad or FLAG (to monitor expression). 
Extracts were also run on SDS polyacrylamide gels, transferred to nitrocellulose and 14-3-3 overlays performed as described in 
the methods. D) GST-Bad, or Ser136/155Ala, Ser112/155Ala or Ser112/136Ala mutants of GST-Bad were transfected into 
HEK-293 cells with either empty pCMV5 vector or FLAG-Pim-1 expression constructs. 24 h after transfection cells were 
serum starved for 18 h and lysed and extracts immunoblotted for total Bad or FLAG (to monitor expression). Extracts were 
also run on SDS polyacrylamide gels, transferred to nitrocellulose and 14-3-3 overlays performed as described in the methods. 
E) GST-Bad was transfected into HEK-293 cells along with either empty pCMV5 vector or active (W) or kinase dead (D) 
FLAG-Pim-1, 2, or 3 expression constructs. 24 h after transfection cells were serum starved for 18 h and were then lysed and 
extracts immunoblotted for total Bad or FLAG (to monitor Pim-1, 2 or 3 expression). Extracts were also run on SDS polyacr-
ylamide gels, transferred to nitrocellulose and 14-3-3 overlays performed as described in the methods. F) As E except that GST 
pull downs were performed on the extracts and immunoblotted for 14-3-3 as described in the methods.BMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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using antibodies specific for the various phosphorylation
sites. Consistent with previous studies [33], stimulation of
the cells with PMA resulted in a modest increase in Ser112
phosphorylation whilst forskolin resulted in increases in
Ser155 phosphorylation and, to a lesser extent, Ser136
(Fig 3B). Co-expression of Pim-1 and Bad resulted in
increased phosphorylation of Ser136 and phosphoryla-
tion of Ser112 and Ser155, when compared to Bad
expressed in the absence of Pim-1. Similar results were
also obtained for co-expression of Pim-2 or Pim-3,
although Pim-2 had a reduced effect on Ser136 phospho-
rylation in Bad compared to co-expression with Pim-1
and Pim-3 (Fig 3B). The phosphorylation of Bad by Pim
kinases was not further increased by PMA stimulation,
although Ser155 phosphorylation was further increased
by Forskolin stimulation. The phosphorylation of Bad
was dependent on the kinase activity of Pim kinases, as
co-expression of kinase dead versions of Pim-1, 2 or 3 and
Bad did not result in the phosphorylation of Bad (Fig 3C).
The ability of Pim-1 to phosphorylate Bad in which one of
the phosphorylation sites had been mutated was also
determined by co-expression. As expected the mutation of
Ser112 to alanine prevented phosphorylation of this site
by Pim-1, but did not significantly affect the phosphoryla-
tion of either Ser136 or Ser155 (Fig 4A). Similarly, muta-
tion of Ser155 prevented phosphorylation of this site by
Pim-1 but did not significantly affect phosphorylation of
Ser112. Surprisingly mutation of Ser155 to alanine did
cause a reduction in the level of Ser136 phosphorylation
by Pim-1 (Fig 4A) and a similar reduction in Ser136 phos-
phorylation was also seen in Ser112/Ser155Ala mutants
(Fig 4B). Mutation of Ser136 to alanine not only blocked
phosphorylation of Ser136 by Pim-1, but also greatly
reduced Ser112 and Ser155 phosphorylation (Fig 4A).
Mutation of Ser136 to an acidic residue to mimic phos-
phorylation was able to restore phosphorylation of
Ser112 and Ser155 (Fig 4A).
Similar effects of the mutants were also seen in the
absence of co-expressed Pim-1, when cells were stimu-
lated with agents to induce the phosphorylation of spe-
cific sites within Bad. PMA promotes Bad Ser112
phosphorylation, probably via RSK, however this was pre-
vented by Ser136 mutation. Forskolin stimulated Ser155
phosphorylation via PKA, and this was also prevented by
mutation of Ser136 [see Additional file 1].
Pim promotes 14-3-3 binding to Bad via phosphorylation 
of Ser136 and dissociation from Bcl-XL
Phosphorylation of a protein can create binding sites for
14-3-3 proteins, and Ser112 and 136 in Bad lie in a poten-
tial consensus 14-3-3 motif [38]. Ser155 does not lie in a
consensus 14-3-3 binding motif, however in vitro phos-
phorylation of Bad by PKA (which predominantly phos-
phorylates Ser155) does promote 14-3-3 interaction [33].
To test the ability of Bad to interact with 14-3-3, GST-Bad
was co-expressed in HEK-293 cells with Pim-1, and 14-3-
3 overlay assays were used to determine if Bad could bind
14-3-3 proteins. In the overlay assay, recombinant 14-3-3
protein was used to detect the presence of proteins on a
Western blot capable of binding 14-3-3. GST-Bad isolated
by glutathione-Sepharose pull downs from the cell lysates
was tested for its ability to bind to 14-3-3. In the absence
of Pim-1 co-expression, GST-Bad was not significantly
phosphorylated on Ser112, 136 or 155 and did not bind
14-3-3 in the overlay assay (Fig 4A and 4C). Co-expres-
sion of Pim-1 however resulted in phosphorylation of all
three sites and promoted interaction of the GST-Bad with
14-3-3 in the overlay assay. Mutation of either Ser112 or
Ser155 to alanine resulted in a modest reduction in the
ability of the Pim-1 phosphorylated GST-Bad to interact
with 14-3-3 proteins in the overlay assay (Fig 4C). As
expected, mutation of Ser136 to alanine, which also
blocks the phosphorylation of Ser112 and Ser155, com-
pletely blocked the ability of GST-Bad to interact with 14-
3-3 proteins. Mutation of Ser136 to an acidic residue also
blocked the ability of Bad to bind to 14-3-3 proteins in the
overlay assay, even though Pim-1 was able to phosphor-
ylate both Ser112 and Ser155 in the Ser136Asp or
Ser136Glu Bad mutants (Fig 4C). These data suggest that
Ser136 is the major 14-3-3 binding site. Consistent with
this, a double mutant of both Ser112 and Ser155 to
alanine, which was phosphorylated on Ser136 (Fig 4B),
was still able to interact with 14-3-3 proteins in the over-
lay assay (Fig 4D). Similar to Pim-1, when Pim-2 or Pim-
3 were co-expressed with GST-Bad, they were also able to
promote 14-3-3 binding in the overlay assay (Fig 4E). To
test if Pim kinases promoted the interaction of Bad and
14-3-3 proteins in cells, Pim kinases and GST-Bad were
co-expressed in HEK-293 cells and the GST-Bad isolated
by glutathione-Sepharose pull downs and blotted for the
presence of endogenous 14-3-3 proteins using a pan 14-3-
3 isoform antibody (Fig 4F). In the absence of Pim kinase
co-expression, 14-3-3 proteins were not detected in the
GST-Bad pull downs, however expression of Pim-1, 2 or 3
was found to promote the binding of 14-3-3 to GST-Bad
in cells (Fig 4F). The ability of Pim kinases to promote the
interaction of Bad and 14-3-3 was dependent on their
kinase activity, as co-expression of kinase dead Pim-1, 2 or
3 did not promote 14-3-3 binding as judged by either co-
precipitation or 14-3-3 overlay assays (Fig 4E and 4F).
Phosphorylation of Bad has been shown to prevent an
interaction with Bcl-XL [39]. The ability of Pim kinases to
prevent the interaction of GST-Bad with endogenous Bcl-
XL was tested in pull down experiments. HeLa cells were
used for these experiments as these cells express detectable
levels of endogenous Bcl-XL.BMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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Phosphorylation of Bad by Pim prevents Bcl-XL binding Figure 5
Phosphorylation of Bad by Pim prevents Bcl-XL binding. A) GST-Bad was transfected into HeLa cells along with either 
empty pCMV5 vector or active (W) or kinase dead (D) FLAG-Pim-1, 2, or 3 expression constructs. 24 h after transfection cells 
were serum starved for 18 h and were then lysed. GST pull downs were then performed on the extracts and imuunoblotted 
for Bcl-XL associating with the GST-Bad. Extracts were also immunoblotted with antibodies against total Bcl-XL, total Bad or 
FLAG. B) GST-Bad, or Ser112Ala, Ser136Ala, Ser155Ala, Ser136Asp or Ser136Glu mutants of GST-Bad were transfected into 
HEK-293 cells along with either empty pCMV5 vector or a FLAG-Pim-1 expression constructs. 24 h after transfection cell 
were serum starved for 18 h and were then lysed. GST pull downs were then performed on the extracts and immunoblotted 
for Bcl-XL associating with the GST-Bad. Extracts were also immunoblotted with antibodies against total Bcl-XL,, total Bad and 
FLAG. C) GST-Bad, or Ser136/155Ala, Ser112/155Ala or Ser112/136Ala mutants of GST-Bad were transfected into HEK-293 
cells with either empty pCMV5 vector or FLAG-Pim-1 expression constructs. 24 h after transfection cells were serum starved 
for 18 h and lysed. GST pull downs were then performed on the extracts and immunoblotted for Bcl-XL associating with the 
GST-Bad. Extracts were also immunoblotted with antibodies against total Bcl-XL, total Bad or FLAG.BMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
Page 10 of 14
(page number not for citation purposes)
As expected, GST-Bad, which was not significantly phos-
phorylated in the absence of kinase co-expression, was
able to interact with Bcl-XL in HeLa cells. Co-expression of
Pim-1, 2 or 3 resulted in phosphorylation of GST-Bad and
reduced the interaction of GST-Bad with Bcl-XL. This was
dependent on the kinase activity of Pim, as co-expression
of kinase dead Pim mutants did not have this effect (Fig
5A). Similar to the 14-3-3 interaction, Ser136 appeared to
be the critical residue involved in this process. Mutation of
Ser112, Ser155 (Fig 5B), or both Ser112 and Ser155 to
alanine (Fig 5C) in Bad did not affect the ability of Pim-1
to prevent the interaction of GST-Bad and Bcl-XL. Muta-
tion of Ser136 in Bad to alanine (which blocked phospho-
rylation of all three sites) or an acidic residue (which did
not affect Ser112 or Ser155 phosphorylation) blocked the
ability of Pim-1 to promote the dissociation of GST-Bad
and Bcl-XL (Fig 5B).
Discussion
Pim-1, 2 or 3 were found to be able to phosphorylate Bad
in vitro and in cells. Pim-2 was found to be the most spe-
cific of the Pim kinases for Ser112 of Bad in vitro, although
it was also able to phosphorylate Ser155 both in vitro and
when over-expressed in HEK-293 cells. Pim-2 was a poor
Ser136 kinase in vitro and, consistent with this, was the
least effective of all the Pim kinases at phosphorylating
this site in cells. In agreement with this Pim-2 has previ-
ously been described to phosphorylate Ser112 [20,21].
Interestingly, the phosphorylation of Ser136 and Ser155
by over-expression of Pim-2 has been suggested to be
dependent on the cell line used [21]. Both previous results
and our results suggest this may reflect different over-
expression levels of Pim-2 achieved in the different cell
types used. Pim-1 was able to phosphorylate Ser112,
Ser136 and Ser155 in Bad, however phosphorylation of
Ser112 was significantly more efficient than phosphoryla-
tion of the other sites in vitro. Pim-1 has previously been
found to phosphorylate Ser112 in Bad, although its abil-
ity to phosphorylate Bad on other sites has not previously
been reported [22]. The ability of Pim-3 to phosphorylate
Bad has not previously been addressed. Here we report
that Pim-3 is also able to phosphorylate Ser112 in Bad.
Interestingly Pim-3 was the most effective kinase in vitro
for Ser136 of Bad. Unlike Pim-1 or Pim-2, which demon-
strated a marked preference for Ser112, Pim-3 was also
effective at phosphorylating Ser136, and to a lesser extent
Ser155, when Bad protein was used as an in vitro substrate
(Table 1). In addition Pim-3 was also able to phosphor-
ylate other sites in Bad including Ser170 in vitro. This site
has been reported to be phosphorylated in vivo, although
the kinase responsible was not identified in the initial
study [36]. Mutagenesis of Ser170 in Bad has suggested
that phosphorylation of this site, like phosphorylation of
Ser112, 136 and 155, inhibits the pro-apoptotic activity of
Bad [36]. Phosphorylation of this site by Pim-3 would
therefore be consistent with the pro-survival function of
Pim-3. To the best of our knowledge, this study is the first
to report a Pim-3 cellular substrate.
The interaction between the phosphorylation sites in Bad
and their roles in Bad function is complex. Phosphoryla-
tion of Ser136 appears to be required for the phosphoryla-
tion of Ser112 and Ser155 to occur when Bad is over-
expressed in cells. Similarly, Ser136 appears to be the
major 14-3-3 binding site in Bad (Fig 4) [38,40], while
Ser155 is suggested to be required for binding to Bcl-XL
[41]. Despite this, phosphorylation of endogenous Bad
on Ser136 has proven hard to demonstrate in vivo. This
may reflect the poor sensitivity of the antibodies available,
however it has also been suggested that this site may not
be physiologically important [42]. In contrast to this,
studies using transfected Bad have suggested that phos-
phorylation of this site is essential for the phosphoryla-
tion of Ser112 and Ser155 and 14-3-3 binding, which are
required to inhibit the apoptotic activity of Bad [38,40].
Studies on Ser112 have suggested that this site may be a
'gatekeeper' site, and that dephosphorylation of this site is
required to recruit a phosphatase that then dephosphor-
ylates Ser136 and Ser155 [43]. An extension of this idea
lead to the proposal that Pim-1 only directly phosphor-
ylates Ser112, and that an increase in Ser136 phosphor-
ylation when Pim-1 was over-expressed was due to a
decrease in the rate of Ser136 dephosphorylation [22].
Whilst this cannot be completely excluded, it is not con-
sistent with our data that Pim-1 can promote the phos-
phorylation of a Ser112Ala Bad mutant in cells. The
interplay between the different Bad phosphorylation sites
is thus very complex and further work is required to com-
pletely understand these mechanisms. An added degree of
complexity is the number of physiological kinases for
Bad, including Pim-1-3, PKB, PAK, RSK, PKA [26-35] and
possibly other kinases potentially playing a role. The exact
context in which Pim phosphorylates Bad in vivo may
therefore depend on both cell type and stimulus and
remains to be fully understood.
The ability of Pim kinases to phosphorylate Bad is consist-
ent with the suggested role of these kinases in pro survival
or proliferation pathways. The finding that all three Pim
kinases can phosphorylate similar sites in Bad could in
part explain the redundancy between Pim kinases in pro-
viding a cellular survival signal. The knockout of Pim
kinase might therefore be expected to have a severe phe-
notype, however a triple knockout of Pim-1, 2 and 3 has
recently been reported. Surprisingly these mice were
found to be viable, and while they were smaller in size
than wild type mice they displayed no obvious health
problems [44]. These mice did however show reduced
proliferation of some haematopoietic cells in response to
growth factors. Interestingly, a triple knockin mutation ofBMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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Bad (resulting in the mutation of Ser112, 136 and 155 to
alanine) in mice was also found to be viable and did not
show increased levels of apoptosis in tissues under nor-
mal conditions [45]. These mice also displayed reduced
numbers of T and B cells and reduced cytokine induced
survival of these cells in vitro, a phenotype with some sim-
ilarity to that of the triple Pim kinase knockout.
Conclusion
We present here biochemical evidence that all three iso-
forms of Pim kinase are able to phosphorylate Bad. The
major site of Bad phosphorylation for all three isoforms of
Pim kinase is Ser112. However, we also demonstrate that
Pim kinases are able to phosphorylate Bad to a lesser
extent on Ser136 and Ser155 in vitro. Interestingly Pim-3
exhibits less specificity for Ser112 than Pim-1 or Pim-2,
and was the most effective pim isoform for Ser136 and
Ser155 phosphorylation in Bad in vitro. We also provide
evidence that Pim kinases may modulate the phosphor-
ylation of Bad on Ser112, Ser136 and Ser155 in HEK-293
cells.
Methods
Plasmids
The coding region for an amino-terminal extended ver-
sion of human Pim-1 (NCBI Acc. NM_002648) predicted
to be synthesised by alternative translation initiation at an
upstream CUG codon [46] was amplified from IMAGE
consortium EST clone 4591723 using primer 5'-
gcgaattcgccaccatggactacaaggacgacgatgacaagctgccgcac-
gagccccacgag-3' incorporating a 5' FLAG tag sequence and
primer 5'- gcgaattcctatttgctgggccccggcgac-3'. The PCR
product was ligated into pCR2.1-TOPO vector (Invitro-
gen), sequenced, and sub-cloned as an EcoR1-EcoR1 insert
into the pCMV5 expression vector [47]. The same coding
region was cloned into expression vector pEBG2T [48]
without the 5' FLAG tag sequence using appropriate prim-
ers as a Spe1-Spe1 insert. The coding region for an amino-
terminal extended version of human Pim-2 (NCBI Acc.
NM_006875.2) predicted to be synthesised by alternative
translation initiation at an upstream CUG codon was
amplified from IMAGE consortium EST clone 3913552
using primer 5'- gcgaattcgccaccatggactacaaggacgacgat-
gacaagctggcgcgcgcggcgaatctcaac-3' incorporating a 5'
FLAG tag sequence and primer 5'- gcggatccttagggtagcaag-
gaccaggccaaag-3'. The PCR product was ligated into
pCR2.1-TOPO vector, sequenced, and sub-cloned as an
EcoR1-BamH1 insert into the pCMV5 expression vector.
The same coding region was cloned into expression vector
pEBG2T without the 5' FLAG tag sequence using appropri-
ate primers as a BamH1-Not1 insert. Nucleotides 125–
1455 (stop codon of CDS) of murine Pim-3 (NCBI Acc.
NM_145478) mRNA were amplified from IMAGE consor-
tium EST clone 4924687 using primer 5'-gcgaattcgagcgtc-
cggcttccccag-3' and primer 5'-
gcgaattctcacttgtcatcgtcgtccttgtagtccaagctctcactgctggaagtg-3'
incorporating a FLAG tag sequence at the 3' end. The PCR
product was ligated into pCR2.1-TOPO vector,
sequenced, and sub-cloned as an EcoR1-EcoR1 insert into
expression vector pCMV5. The same region of Pim-3
mRNA was cloned (lacking the Pim-3 stop codon) with a
C-terminal GST sequence (generated by overlap PCR) into
pCMV5 as a Kpn1/HindIII insert. The Pim-3 sequence was
also cloned with an N-terminal His Tag in to a pFastBAC
vector for expression in Baculovirus expression. Kinase
dead versions of the Pim-1, Pim-2 and Pim-3 expression
constructs were generated by mutating the 'DFG' motif to
'AFG' in each case using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene). A cDNA encoding full-
length murine Bad was amplified from the pGEX Bad con-
struct described in [33] using primer 5'- gcggatccatgggaac-
cccaaagcagccctc-3' and primer 5'-
gtgcggccgctcactgggagggggtggagcc-3'. The PCR product was
ligated into pCR2.1-TOPO vector, sequenced, and sub-
cloned as a BamH1-Not1 insert into expression vector
pEBG6P-1 (pEBG2T containing a PreScission Protease
site). S112A, S155A, S136A, S136D and S136E mutants
were generated using the QuikChange Site-Directed Muta-
genesis Kit (Stratagene).
Cell culture
HEK-293 cells were maintained in DMEM containing
10% FBS (Sigma), 2 mM L-glutamine, 50 units/ml peni-
cillin G and 50 µg/ml streptomycin (Invitrogen). Cells
were transfected using PEI as described [49]. Prior to stim-
ulation and analysis cells were starved in DMEM lacking
serum for eighteen hours at 37°C and 5% CO2. Cells were
stimulated with IGF (100 ng/ml 5 min), sorbitol (0.5 M
for 30 min), AICar (2 mM for 1 hour), UV-C (200 Jm2/10
sec followed by 1 hour incubation at 37°C), hydrogen
peroxide (1 mM for 1 hour), PMA (400 ng/ml for 15
min), anisomycin (10 µg/ml for 1 hour) or Forskolin (20
µM for 30 min). Cells were lysed in 50 mM Tris-HCl pH
7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovana-
date, 50 mM sodium fluoride, 1 mM sodium pyrophos-
phate, 0.27 M sucrose, 1% (v/v) Triton X-100, 0.1% (v/v)
2-mercaptoethanol. Lysates were clarified at 13,000 rpm
for 5 min at 4°C and the supernatants quick frozen in liq-
uid nitrogen and stored at -80°C until used.
Peptide kinase assay
For in vitro kinase assays 1 unit of activity was defined as
the amount of kinase that catalysed the phosphorylation
of 1 nmol of substrate in 1 min into the peptide
RSRMSSYPDRG at a 30 µM peptide concentration. To
determine the ability of Pim kinases to phosphorylate
peptides derived from Bad, each peptide substrate was
used at the concentrations indicated and incubated with
10 mU of kinase in a 50 µl volume for 10 min at 30°C in
10 mM MgCl2 – 0.1 mM [γ32P]-ATP, 50 mM Tris-HCl, pHBMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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7.5, 10 mM EGTA, 0.1% 2-mercaptoethanol and 2.5 µM
PKI. Reactions were terminated by spotting on to p81
paper, followed by immersion in 50 mM ortho-phos-
phoric acid. All papers were then washed three times in 50
mM ortho-phosphoric acid to remove unincorporated
ATP, once in acetone and then dried and the 32P incorpo-
ration was determined by Cerenkov counting. The pep-
tides used were RSRMSSYPDRG (corresponding to
Ser112), RGSRSAPPNL (corresponding to Ser136) and
RELRRMSDEFEGS (corresponding to Ser155).
To determine the activity of Pim kinases expressed in Hek-
293 cells, FLAG-Pim kinase was immunoprecipitated
from 50 µg of soluble cell lysate using an anti FLAG anti-
body (Sigma) and assayed by standard protocols [50].
Briefly, immunoprecipitates were washed twice in 0.5 M
NaCl, 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA and 0.1%
(v/v) 2-mercaptoethanol and once in 50 mM Tris-HCl pH
7.5, 0.1 mM EGTA and 0.1% (v/v) 2-mercaptoethanol.
Precipitates were then resuspended in 35 µl of reaction
buffer (containing Tris/HCl pH7.5, EGTA, PKI and
RSRMSSYPDRG substrate peptide,), and the reaction was
started by the addition of 10 µl 50 mM MgAc, 0.5 mM
[γ32P]-ATP and incubated at 30°C for 15 min. Final con-
centrations of reagents in the assay were 50 mM Tris/HCl
pH7.5, 0.1 mM EGTA 0.1% 2-mercaptoethanol 2.5 µM
PKI (an inhibitor of PKA), 30 µM substrate peptide pep-
tide, 10 mM MgAc and 0.1 mM [γ32P]-ATP. Reactions were
stopped by transfer onto P81 paper and washing in 75
mM orthophosphoric acid.
In vitro Bad phosphorylation
Human Pim-1 and Pim-2 were cloned with an N-terminal
GST-tag and expressed in HEK-293 cells. Murine Pim-3
was cloned with an N-terminal His-tag and expressed in a
Baculovirus expression system using Sf9 insect cells.
Murine Bad was cloned with an N-terminal GST-tag and
expressed in bacteria. All recombinant proteins were puri-
fied using standard affinity chromatography techniques
on glutathione or Ni-NTA sepharose as appropiate. Puri-
fied recombinant Pim-kinases (10 mU) were incubated
with 2 µg of recombinant Bad over the indicated time
period in 50 mM Tris-HCl, pH 7.5, 10 mM EGTA, 0.1% 2-
mercaptoethanol, 2.5 µM PKI, 10 mM MgCl2 and 0.1 mM
[γ32P]-ATP. Reactions were stopped by the addition of
SDS loading buffer and samples analysed on a 4–12%
Novex gel (Invitrogen). Protein was detected by Colloidal
blue staining and the appropriate band was excised and
the amount of 32P incorporation was determined by Cer-
encov counting.
Phosphorylation site identification
Samples were run on a 4–12% polyacrylamide gel, and
the substrate band was excised and the amount of 32P
incorporated determined by Cerenkov counting. For
phospho site mapping, the protein was reduced with
dithiothreitol, alkylated with iodoacetamide and digested
with trypsin. The resulting peptides were applied to a
Vydac 218TP5215 C18 column equilibrated in 0.1% trif-
luoroacetic acid and the column developed with a linear
gradient of acetonitrile/0.1% trifluoroacetic acid at a flow
rate of 0.2 ml/min while collecting 0.1 ml fractions. 32P
radioactivity was recorded with an on-line monitor. Phos-
phorylation site mapping was performed essentially as
described previously [51]. Identification of 32P labelled
peptides was performed by MALDI-TOF and MALDI-TOF-
TOF mass spectrometry on an Applied Biosystems 4700
using a matrix of 10 mg/ml alpha-cyanocinnamic acid in
50% acetonitrile/0.1% trifluoroacetic acid/10 mM ammo-
nium phosphate. Sites of phosphorylation within the
peptides were determined by a combination of MALDI-
TOF-TOF mass spectrometry and solid phase Edman
sequencing. Solid phase sequencing was performed on an
Applied Biosystems Procise 494C after coupling the pep-
tide covalently to a Sequelon-arylamine membrane and
measuring by Cerenkov counting the 32P radioactivity
released after each cycle.
GST-Bad pull down
Lysates were incubated with glutathione-sepharose for 2
hours at 4°C. Immunoprecipitates were pelleted by cen-
trifugation for 1 min at 13,000 g and washed twice in 50
mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.1 mM EGTA and
0.1 % 2-mercaptoethanol and once in 50 mM Tris-HCl,
pH 7.5, 0.1 mM EGTA and 0.1 % 2-mercaptoethanol. Pro-
tein complexes were eluted in SDS sample buffer.
Immunoblotting
Soluble cell extract was run on 4–12% Novex gels (Invit-
rogen) and transferred onto nitrocellulose membranes
and blotted using standard techniques. Antibodies that
recognise p-Bad (Ser112), p-Bad (Ser 136), pBad (Ser155)
and Bcl-XL were from Cell Signalling Technology. An anti-
body that detected total Bad protein was raised in-house.
The Flag antibody was from Sigma and HRP conjugated
secondary antibodies were from Pierce (Cheshire, UK)
and blots were developed using the enhanced ECL reagent
(Amersham, Buckinghamshire, UK).
14-3-3 overlay assays
14-3-3 overlay assays were performed as described [52].
Briefly, proteins from cell extracts or GST pull downs were
separated on 4–12% Novex gels (Invitrogen) and trans-
ferred to nitrocellulose membrane. Membranes were then
treated as for immunoblots. Digoxygenin (DIG)-labelled
14-3-3 proteins were incubated with the membranes in
place of the primary antibody, followed by incubation
with a secondary anti-DIG horseradish peroxidase anti-
body. Blots were developed using the enhanced ECL rea-
gent (Amersham, Buckinghamshire, UK).BMC Cell Biology 2006, 7:1 http://www.biomedcentral.com/1471-2121/7/1
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Abbreviations
PIM (proviral integration of MMLV), PKA (cAMP-depend-
ent protein kinase), RSK (p90 ribosomal S6 kinase), PAK
(p21 activated protein kinase), PKI (cAMP-dependent
protein kinase inhibitor peptide), GST (glutathione S-
transferase), ECL (enhanced chemiluminescence), IGF
(insulin-like growth factor), PMA (phorbol 12-myristate
13-acetate), HEK (human embryonic kidney), DMEM
(Dulbecco's modified eagles medium).
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